Lumida
/RCEL
⌘K
AVITA Medical Inc

AVITA Medical Inc

RCEL
$9.88USD+0.20%+0.02 today

MARKET CAP

305.6M

P/E (TTM)

FWD P/E

DAY RANGE

$10 – $10

52W RANGE

$3
$11

AI Summary

Stalk
TrimMedium

RCEL remains in a sustained Stage 4 decline with persistent lower highs and lower lows and price below all key moving averages. Oversold conditions at current levels increase the risk of a bounce, so under the speculative strategy we defer selling to rallies into resistance around the EMAs to ensure asymmetric entry.

  • Q2 revenue of $21.7M grew 18% YoY driven by RECELL sales.
  • Full-year 2026 revenue guidance boosted to $86–89M with Q4 cash-flow breakeven forecast.
  • Negative earnings yield and weak book-to-price suggest rich valuation.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$29.2M$34.4M$50.1M$64.3M$71.6M
YoY %+104.9%+17.8%+45.7%+28.1%+11.5%
P / Sales15.9x4.7x6.9x5.2x1.3x
EV / Sales15.9x4.5x7.7x6.1x2.2x
Gross Profit, Adj.$23.3M$28.4M$42.4M$55.2M$58.8M
YoY %+106.2%+21.9%+49.3%+30.2%+6.6%
Margin %79.6%82.4%84.5%85.8%82.1%
EV / Gross Profit20.0x5.5x9.1x7.1x2.7x
EBITDA, Adj.$-25.7M$-26.6M$-41.7M$-55.5M$-40.2M
YoY %+39.1%-3.5%-56.7%-33.1%+27.5%
Margin %-87.9%-77.3%-83.1%-86.3%-56.1%
EV / EBITDA-18.1x-5.9x-9.2x-7.1x-4.0x
EBIT$-26.5M$-27.5M$-42.7M$-56.6M$-42.5M
YoY %+37.8%-3.6%-55.1%-32.7%+24.8%
Margin %-90.8%-79.9%-85.1%-88.1%-59.4%
EV / EBIT-17.5x-5.7x-9.0x-6.9x-3.7x
Net Income$-26.6M$-26.7M$-35.4M$-61.8M$-48.6M
YoY %+36.8%-0.3%-32.7%-74.8%+21.4%
Net Margin-90.9%-77.5%-70.6%-96.3%-67.8%
EPS (GAAP)-$1.17-$1.07-$1.40-$2.39-$1.74
YoY %+43.5%+8.5%-30.8%-70.7%+27.2%